HOME
PRODUCTS
COMPANY
CONTACT
FAQ
Research
Dictionary
Pharma
Sign Up
FREE
or
Login
Username:
Password:
Remember login
Login
Send password reminder...
Ethoglucid (Etoglucid)
Alkylating antineoplastic agent used especially in bladder neoplasms. It is toxic to hair follicles, gastro-intestinal tract, and vasculature.
Also Known As:
Etoglucid
; Epodyl; Oxirane, 2,2'-(2,5,8,11-tetraoxadodecane-1,12-diyl)bis-
Networked:
37
relevant articles (
5
outcomes,
7
trials/studies)
Relationship Network
Bio-Agent Context: Research Results
Organic Chemicals: 133
Ethers: 242
Ethoglucid: 37
Cyclic Ethers: 12
Epoxy Compounds: 689
Ethoglucid: 37
Related Diseases
1.
Neoplasms (Cancer)
03/02/1984 - "
Studies on the absorption of Ethoglucid from human urinary bladder, utilizing a photometric method to determine Ethoglucid in biological fluids, gave the following results: The intact uroepithelium prevents absorption of interluminal Ethoglucid as well as no significant increase of absorption was seen in the presence of superficial, highly differentiated cancers or inflammatory alterations of the bladder.
"
01/01/1992 - "
For 156 patients treated with Epodyl, the recurrence rate was 0.29 and the tumor rate was 0.57.
"
03/02/1984 - "
Urothelial lesions after transurethral resection or infiltrating cancers permit an intercellular diffusion of Ethoglucid from the bladder cavity into the systemic circulation, due to a loss of intercellular gaps between the urothelial elements.
"
05/01/1978 - "
Apart from a few local side effects, the response of the tumor to Epodyl was very good as assessed up to three years.
"
05/01/1978 - "
Epodyl in management of noninvasive vesical neoplasms.
"
2.
Transitional Cell Carcinoma
01/01/1991 - "
In a prospective randomised controlled study, the efficacy of ethoglucid was compared with that of keyhole-limpet haemocyanin (KLH) in preventing recurrent tumours following transurethral resection of primary superficial transitional cell carcinoma of the bladder.
"
06/01/1988 - "
The ultrastructure of transitional cell carcinomas of the human urinary bladder treated with ethoglucid or mitomycin.
"
01/01/1988 - "
All patients had a history of recurrent multiple noninvasive superficial transitional cell carcinoma of the bladder, and were previously unsuccessfully treated with intravesical chemotherapy (epodyl and/or adriamycin).
"
03/01/1994 - "
A prospective randomized controlled study on the effect of KLH (keyhole limpet hemocyanin) versus etoglucid in the prevention of recurrences in primary and recurrent superficial transitional cell carcinoma of the bladder (stage pTa-pT1, grades 1-3 according to the recommendations of UICC and WHO) after complete transurethral resection of the tumor started in 198.
"
08/01/1990 - "
A multicenter, prospective, randomized controlled study was begun in 1985 on the effect of ethoglucid and keyhole-limpet hemocyanin in the prevention of recurrent superficial transitional cell carcinoma of the bladder (stages pTa to pT1, grades 1 to 3 according to the recommendation of the International Union Against Cancer and the World Health Organization).
"
3.
Carcinoma (Carcinomatosis)
03/01/1989 - "
These results demonstrate that the decision of whether superficial bladder carcinomas are to be treated with short- or long-term Epodyl should be based on tumor-associated risk factors.
"
08/01/1997 - "
We compared the efficacy of transurethral resection alone or transurethral resection followed by bladder instillations of doxorubicin or ethoglucid for 1 year in patients with superficial bladder carcinoma, and followed them long term for the incidence of progression to muscle invasion.
"
06/01/1988 - "
Electron microscopy studies of the ultrastructure of bladder carcinoma treated by intravesical instillation of ethoglucid and mitomycin are described.
"
08/01/1997 - "
Adjuvant chemotherapy for superficial transitional cell bladder carcinoma: long-term results of a European Organization for Research and Treatment of Cancer randomized trial comparing doxorubicin, ethoglucid and transurethral resection alone.
"
4.
Urinary Bladder Neoplasms (Bladder Cancer)
12/01/1977 - "
Of 48 patients with bladder tumors treated with intravesical epodyl 17 have shown a complete remission at some stage of treatment, although several have relapsed later.
"
03/01/1982 - "
Results from a retrospective analysis of 139 patients with recurrent superficial bladder tumors treated by intravesical epodyl are reviewed.
"
01/10/1976 - "
[Epodyl treatment of bladder neoplasms].
"
01/01/1990 - "
Long-term follow-up of intravesical Epodyl therapy for superficial bladder cancer.
"
03/01/1989 - "
[Short-term versus long-term chemoprevention of recurrence with Epodyl following transurethral resection of superficial urinary bladder cancer].
"
5.
Cystitis
01/01/1979 - "
Irritative cystitis occurred in 16 per cent of the series, and in these cases Epodyl treatment had to be stopped.
"
08/01/1984 - "
Mild systemic toxicity and chemical cystitis were observed in 3 and 3 per cent, respectively, of the patients given ethoglucid, and in 5 and 4 per cent, respectively, of those taking doxorubicin.
"
Related Drugs and Biologics
1.
Doxorubicin (Adriamycin)
2.
Thiotepa (Triethylenethiophosphoramide)
3.
keyhole-limpet hemocyanin (keyhole limpet hemocyanin)
4.
Mitomycin (Mitomycin-C)
5.
Interferons
6.
Ethoglucid (Etoglucid)
7.
Epirubicin (Ellence)
8.
Cisplatin (Platino)
9.
Anthracyclines
10.
Paclitaxel (Taxol)
Related Therapies and Procedures
1.
Intravesical Administration
2.
Therapeutics
3.
Drug Therapy (Chemotherapy)
4.
Adjuvant Chemotherapy
5.
Chemoprevention